UTHR counsel sells shares after option exercise
UNITED THERAPEUTICS Corp executive vice president and general counsel Paul A. Mahon reported an exercise-and-sell transaction in company stock.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp executive vice president and general counsel Paul A. Mahon reported an exercise-and-sell transaction in company stock. He exercised stock options covering 8,300 shares of common stock at $146.03 per share and, on the same date, sold 8,300 shares in a series of open-market trades at prices generally around $543–$549 per share. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan that Mahon entered into on August 11, 2025. Following these transactions, he directly holds 45,172 shares of UNITED THERAPEUTICS common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,300 shares ($3.33M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
MAHON PAUL A
Role
EVP & GENERAL COUNSEL
Sold
8,300 shs ($4.54M)
Approx. gross sale proceeds
$4.54M
Approx. exercise cost
$1.21M
Approx. pre-tax spread
$3.33M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 8,300 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,300 | $146.03 | $1.21M |
| Sale | Common Stock | 200 | $539.76 | $108K |
| Sale | Common Stock | 840 | $543.8893 | $457K |
| Sale | Common Stock | 374 | $545.2671 | $204K |
| Sale | Common Stock | 2,627 | $546.4178 | $1.44M |
| Sale | Common Stock | 935 | $547.1108 | $512K |
| Sale | Common Stock | 1,481 | $548.425 | $812K |
| Sale | Common Stock | 593 | $549.4948 | $326K |
| Sale | Common Stock | 1,250 | $549.47 | $687K |
Holdings After Transaction:
Stock Option — 105,640 contracts (Direct);
Common Stock — 45,172 shares (Direct)
Footnotes (7)
- F1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $543.59 to $544.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $544.795 to $545.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $545.80 to $546.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $546.80 to $547.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $547.90 to $548.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $549.12 to $549.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 8,300 shares
Sale prices: $543–$549 per share
Options exercised: 8,300 shares
+4 more
7 metrics
Shares sold
8,300 shares
Open-market sales of UNITED THERAPEUTICS common stock on June 4, 2026
Sale prices
$543–$549 per share
Weighted-average price ranges for grouped trades on June 4, 2026
Options exercised
8,300 shares
Stock options converted into common stock on June 4, 2026
Option exercise price
$146.03 per share
Exercise price for 8,300-share stock option grant
Post-transaction holdings
45,172 shares
Common stock directly held after reported transactions
10b5-1 plan date
August 11, 2025
Date Mahon entered pre-arranged trading plan covering these trades
Option expiration
March 15, 2027
Expiration date of exercised stock options
Key Terms
Rule 10b5-1 trading plan, open-market sale, stock options, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_code_description: Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
stock options financial
"This is an exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did UTHR executive Paul Mahon report in this Form 4 filing?
Paul Mahon reported exercising stock options for 8,300 UNITED THERAPEUTICS shares and selling 8,300 shares in open-market trades. The transaction reflects an exercise-and-sell pattern rather than a simple open-market purchase of new shares.
At what price were Paul Mahon’s UTHR stock options exercised?
Paul Mahon exercised stock options covering 8,300 UNITED THERAPEUTICS shares at an exercise price of $146.03 per share. These options related to grants exercisable from March 15, 2020 and expiring on March 15, 2027, as disclosed in the derivative transaction data.
What is the significance of the multiple price ranges in Mahon’s UTHR trades?
Several sales were executed in multiple trades within specified price ranges, such as $543.59 to $544.03 per share. The Form 4 reports a weighted-average price for each group and notes Mahon can provide detailed trade breakdowns to regulators or shareholders upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
